Utama › Limfoma Bukan Hodgkin › Texas › Dallas
Kajian klinikal Limfoma Bukan Hodgkin di Dallas, TX
17 kajian untuk Limfoma Bukan Hodgkin sedang mencari peserta di lokasi dalam dan sekitar Dallas (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Mengambil pesertaFasa 2
- UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Mengambil pesertaFasa 1/2
- Baylor Scott & White Research Institute, Texas Oncology, Dallas
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Mengambil pesertaFasa 1
- University of Texas Southwestern, Dallas
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Mengambil pesertaFasa 1
- Texas Oncology - DFW (Sammons CC), Dallas
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Mengambil pesertaFasa 1
- Baylor University Medical Center, Dallas
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Mengambil pesertaFasa 1/2
- Baylor University Medical Center, Dallas
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Mengambil pesertaKajian pemerhatian
- UT Southwestern Medical Center, Dallas
DALY II USA/ MB-CART2019.1 for DLBCL
Mengambil pesertaFasa 2
- UT Southwestern Medical Center, Dallas
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Mengambil pesertaKajian pemerhatian
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Mengambil pesertaFasa 1/2
- University of Texas Southwestern Medical Center, Dallas
Study of SGR-1505 in Mature B-Cell Neoplasms
Mengambil pesertaFasa 1
- University of Texas Southwestern, Dallas
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Mengambil pesertaFasa 1
- UT Southwestern Medical Center, Dallas
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Mengambil pesertaKajian pemerhatian
- Ut Southwestern, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Dallas
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Mengambil pesertaKajian pemerhatian
- University of Texas Southwestern, Dallas
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Mengambil pesertaFasa 1
- University of Texas Southwestern Medical Center, Dallas
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Mengambil pesertaFasa 1/2
- UT Southwestern Medical Center, Dallas
Kajian Limfoma Bukan Hodgkin di bandar lain
- New York City, NY31 kajian
- Houston, TX31 kajian
- Boston, MA26 kajian
- Nashville, TN21 kajian
- Philadelphia, PA20 kajian
- Baldwin Park, CA19 kajian
- Washington, DC18 kajian
- Chicago, IL18 kajian
- Atlanta, GA18 kajian
- Milwaukee, WI18 kajian
- Columbus, OH18 kajian
- Seattle, WA16 kajian
Kajian lain di Dallas
- Kanser Payudara55 kajian
- Kanser Paru-paru Bukan Sel Kecil52 kajian
- Kanser Metastatik42 kajian
- Kegagalan Jantung42 kajian
- Kanser (semua jenis)37 kajian
- Kanser Prostat36 kajian
- Kanser Kolorektal33 kajian
- Obesiti30 kajian
- Kanser Ovari28 kajian
- Kanser Paru-paru27 kajian
- Kanser Pundi Kencing27 kajian
- Kanser Endometrium24 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.